$FTRE News

This Stock Is Hot at New 52-Week Highs. But It Now for Profit Growth Ahead.

Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development

Fortrea And Omico Collaborate To Accelerate Precision Oncology Research By Helping Connect Cancer Patients To Biomarker-Matched Clinical Trials

UBS Maintains Neutral on Fortrea Holdings, Raises Price Target to $24

Fortrea Completes Acquisition of the Early Phase Services Division from Worldwide Clinical Trials

Is Fortrea Holdings (FTRE) Still Cheap After Its 116% Run?

Deutsche Bank Upgrades Fortrea Holdings to Buy, Raises Price Target to $25

Fortrea (FTRE) Stock Trades Up, Here Is Why

Barclays Upgrades Fortrea Holdings to Overweight, Raises Price Target to $23

Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call

UBS Initiates Coverage On Fortrea Holdings with Neutral Rating, Announces Price Target of $22

Fortrea (FTRE) Stock Could Be 46% Undervalued As Deal Questions Build

Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Fortrea to Participate in September Investor Conferences

Fortrea Reinstates Jason Knoblauch As CFO

Fortrea: A Surprising M&A Move During The Recovery

Fortrea (FTRE) Stock Is Up, What You Need To Know

Fortrea Leverages Early Phase Strengths to Accelerate Market Expansion

Fortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical Trials

Fortrea to Acquire the Early Phase Services business from Worldwide in an all-cash transaction valued at approximately $45M.